Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma
The purpose of this study is to collect blood samples and study cancer cells found in these blood samples from patients with pancreatic cancer. Prior research has discovered that tumor cells can be collected from the blood of patients with pancreatic and other cancers.
The physicians have developed techniques for isolating and analyzing cancer cells using a simple blood test. They will study how these cells relate to how chemotherapy works. They hope to use this information to guide choices of treatment for patients in the future.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma|
- isolating and enriching circulating tumorigenic cells [ Time Frame: 1 year ] [ Designated as safety issue: No ]A 10 mL blood sample will be drawn from participants prior to starting chemotherapy treatment. circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients. During the 1 year following enrollment, in the setting of disease progression, a subsequent 10 mL blood sample may be drawn from participants prior to changing chemotherapy treatment.
- successful gene expression profiling [ Time Frame: 1 year ] [ Designated as safety issue: No ]of these circulating tumorigenic cells. For each blood sample collected, CTCs will be isolated, expanded, RNA extracted, gene expresion analysis performed and treatment profile sensitivity performed.
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2017|
|Estimated Primary Completion Date:||November 2017 (Final data collection date for primary outcome measure)|
Pts with Pancreatic Adenocarcinoma
This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
Other: Blood draw
Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01474564
|Contact: Kenneth Yu, M.D., M.Sc.||646-888-4188|
|Contact: Eileen O'Reilly, MD||646-888-4182|
|United States, New York|
|Memorial Sloan Kettering Cancer Center @ Suffolk||Recruiting|
|Commack, New York, United States, 11725|
|Contact: Kenneth Yu, MD, M.Sc, 646-888-4188|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Kenneth Yu, M.D., M.Sc. 646-888-4188|
|Contact: Eileen O'Reilly, MD 646-888-4182|
|Principal Investigator: Kenneth Yu, MD, M.Sc|
|Memorial Sloan Kettering at Mercy Medical Center||Recruiting|
|Rockville Centre, New York, United States|
|Contact: Kennneth Yu, MD, M.Sc 646-888-4188|
|Memoral Sloan Kettering Cancer Center at Phelps||Recruiting|
|Sleepy Hollow, New York, United States, 10591|
|Contact: Kenneth Yu, MD, M.Sc 646-888-4188|
|Memorial Sloan Kettering West Harrison||Recruiting|
|West Harrison, New York, United States, 10604|
|Contact: Kenneth Yu, M.Sc. 646-888-4188|
|Principal Investigator:||Kenneth Yu, M.D., M.Sc.||Memorial Sloan Kettering Cancer Center|